MODERNA BIOTECH DISTRIBUTOR UK LTD

• ◆

  Outstanding charges registered

  One or more mortgages or charges remain undischarged on the Companies House register.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Therefore, having reviewed the Company's expected cash outflows for the period to 31 December 2026, and confirmed the support from the ultimate parent from Moderna, Inc. covering the same period, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for a period of at least 12 months from the approval of the financial statements.”

Significant events

• “The Company was incorporated on 28 June 2022 and, until 1 April 2023, was not engaged in business activities other than those related to its formation and establishment. On that date, Moderna Biotech UK Ltd. transferred its entire sales and distribution business to Moderna Biotech Distributor UK Ltd. under a Business Transfer Agreement, which included contracts, assets, liabilities, employees, and certain benefits. The transaction, executed for a nominal consideration of £1, was undertaken to align each entity with its respective specialization. In line with this transition, the original supply agreement with the UK Government (UK Health and Security Agency), initially signed with Moderna Switzerland GmbH, was transferred to Moderna Biotech Distributor UK Ltd. once it received the necessary authorization in 2024. Sales under this agreement commenced in September 2024.”
• “Effective 1 January 2024, 26 employees were transferred from Moderna Biotech Distributor UK Ltd. to Moderna Biotech Manufacturing UK Ltd. under the Transfer of Undertakings (Protection of Employment) Regulations 2006 (TUPE). The transfer preserved continuity of employment, with no adverse changes to terms or benefits. This move formed part of the Group's legal entity alignment in the UK and had no adverse impact on employees' rights.”
• “The Company commenced commercial sales in September 2024 under the Framework Development and Supply Agreement with the UK Government (UKHSA).”
• “Transfer of the UKHSA contract from Moderna Switzerland GmbH to Moderna Biotech Distributor UK Ltd., enabling the start of UK sales.”
• “Transfer of 26 employees to Moderna Biotech Manufacturing UK Ltd. to align staffing with operational responsibilities.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

0

last 24 months

Officers appointed

2

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +2,484.5%

  £15,696,300 → £405,668,625

• Cash

  -72.9%

  £4,810,725 → £1,305,723

• Net assets

  +113%

  £4,229,322 → £9,010,407

• Employees

  -43.3%

  30 → 17

• Operating profit

  +1,149.9%

  £547,761 → £6,846,440

• Profit before tax

  +991.7%

  £668,504 → £7,297,818

• Wages

  -61.9%

  £7,244,363 → £2,760,596

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers